Q3 2024 MaxCyte Inc Earnings Call Transcript
Key Points
- MaxCyte Inc (MXCT) reported a total revenue of $8.2 million for the third quarter, exceeding internal expectations.
- The company signed a record number of six new strategic platform licenses (SPLs) in 2024, indicating strong demand for its platform.
- Processing Assembly (PA) revenue grew by 54% year over year, driven by broad-based customer development.
- MaxCyte Inc (MXCT) increased its core revenue growth expectations for 2024, reflecting confidence in underlying business trends.
- The company maintains a healthy cash position with $196.6 million in cash and cash equivalents and no debt.
- Instrument revenue was impacted by continued customer caution on capital equipment spending.
- Gross margin declined to 76% from 90% in the previous year due to a one-time inventory write-off.
- Revenue from drug discovery customers declined by 14% year over year.
- SPL program-related revenue was immaterial compared to the previous year, indicating variability in milestone payments.
- The funding environment remains largely unchanged, with customers operating with a cautious mindset.
Third quarter earnings conference call. At this time. All participants are in listen-only mode. After the speaker presentation, there will be a question and answer session to ask the question during the session. You would need to press star 11 on your telephone.
You would then hear an automated message advising your hand is raised to withdraw your question. Please press star 11 again.
I would now like to hand the conference over to Scott Feinberg of Investor Relations. You may begin.
Good afternoon, everyone. My name is Scott Feinberg, and I am responsible for investor relations here at MaxCyte.
Thank you for participating in today's conference call. Joining me on the call from MaxCyte. We have Maher Masoud, President and Chief Executive Officer and Doug Swirsky, Chief Financial Officer.
Earlier today MaxCyte released financial results for the third quarter ended September 30th 2024.
A copy of the press release is available on the company's website.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
